Meeting
2023 ASCO Annual Meeting
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Authors
Nirav Niranjan Shah
Medical College of Wisconsin, Milwaukee, WI
Nirav Niranjan Shah , Wojciech Jurczak , Pier Luigi Zinzani , Toby A. Eyre , Chan Cheah , Chaitra Shankar Ujjani , Koji Izutsu , Shuo Ma , Ian W. Flinn , Alvaro Jose Alencar , David John Lewis , Krish Patel , Kami J. Maddocks , Yucai Wang , Talha Munir , Andrew David Zelenetz , Minna Balbas , Donald E Tsai , Chunxiao Wang , Michael Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT03740529
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7514)
DOI
10.1200/JCO.2023.41.16_suppl.7514
Abstract #
7514
Poster Bd #
65
Abstract Disclosures
Similar Posters
First Author: Tycel Jovelle Phillips
Poster
2023 ASCO Annual Meeting
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
First Author: Shubham Pant
Poster
2023 ASCO Annual Meeting
Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.
First Author: Xiaochun Zhang
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely